Refractory cancer
Information
- Disease name
- Refractory cancer
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05990920 | Active, not recruiting | Phase 1 | Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy | August 23, 2023 | December 2024 |
| NCT03187288 | Active, not recruiting | Phase 1 | Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS | May 25, 2018 | June 30, 2024 |
| NCT04861987 | Active, not recruiting | Phase 1 | A Study of the Safety and PK of PCS6422 (Eniluracil) With Capecitabine in Patients With Advanced, Refractory GI Tract Tumors | June 18, 2021 | August 10, 2024 |
| NCT03678883 | Active, not recruiting | Phase 2 | 9-ING-41 in Patients With Advanced Cancers | January 4, 2019 | November 2025 |
| NCT03336931 | Active, not recruiting | PRecISion Medicine for Children With Cancer | September 5, 2017 | December 2032 | |
| NCT03445858 | Active, not recruiting | Early Phase 1 | Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults | February 12, 2018 | January 12, 2025 |
| NCT04310345 | Active, not recruiting | N/A | Impact of Human-Animal Interactions on Children With Life-Threatening Conditions and Their Parents | March 31, 2021 | February 2025 |
| NCT03765099 | Completed | N/A | Animal-Assisted Interactions in Children With Life-Threatening Conditions and Their Parents | February 21, 2019 | December 31, 2022 |
| NCT00551850 | Completed | Phase 1 | A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients | October 2007 | May 2010 |
| NCT00011414 | Completed | Phase 1 | Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors | February 15, 2001 | January 13, 2016 |
| NCT02630199 | Completed | Phase 1 | Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer | December 2015 | April 19, 2021 |
| NCT03206073 | Completed | Phase 1/Phase 2 | A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer | December 7, 2017 | June 30, 2022 |
| NCT03441100 | Completed | Phase 1 | TCR-engineered T Cells in Solid Tumors: IMA202-101 | May 2, 2019 | March 17, 2023 |
| NCT03760952 | Completed | Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling | February 26, 2019 | November 15, 2022 | |
| NCT03941262 | Completed | Phase 1 | Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy | July 15, 2019 | February 17, 2023 |
| NCT00530192 | Completed | Early Phase 1 | Molecular Profiling Protocol (SCRI-CA-001) | September 2006 | March 2009 |
| NCT06208657 | Not yet recruiting | Phase 1/Phase 2 | Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer | March 2024 | December 2035 |
| NCT06251076 | Not yet recruiting | Phase 4 | Plan Development for Giving Teclistamab in the Outpatient Setting | April 15, 2024 | September 4, 2025 |
| NCT06372574 | Recruiting | Phase 1 | A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors | July 1, 2024 | February 1, 2028 |
| NCT03686124 | Recruiting | Phase 1 | ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors | May 14, 2019 | December 2028 |
| NCT04239092 | Recruiting | Phase 1 | 9-ING-41 in Pediatric Patients With Refractory Malignancies. | June 5, 2020 | December 2024 |
| NCT05693831 | Recruiting | myCare-102: Clinical Utility and Usability of Cellworks Singula™ and Cellworks Ventura™ Reports | December 1, 2022 | December 1, 2025 | |
| NCT05852717 | Recruiting | Phase 2 | Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma | October 31, 2023 | June 2025 |
| NCT05856981 | Recruiting | Phase 1 | Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors | April 3, 2023 | December 2025 |
| NCT05859074 | Recruiting | Phase 1 | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | May 4, 2023 | May 4, 2028 |
| NCT05864144 | Recruiting | Phase 1/Phase 2 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | May 31, 2023 | June 2027 |
| NCT05958121 | Recruiting | Phase 1/Phase 2 | IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors | August 9, 2023 | September 2027 |
| NCT06024603 | Recruiting | N/A | Individualized Treatments in Adults With Relapsed/Refractory Cancers | November 20, 2023 | November 1, 2025 |
| NCT06096038 | Recruiting | Phase 1/Phase 2 | Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC | April 5, 2024 | August 2028 |
| NCT06104488 | Recruiting | Phase 1 | A Study of Avutometinib for People With Solid Tumor Cancers | October 20, 2023 | October 20, 2029 |
| NCT06184035 | Recruiting | Phase 1/Phase 2 | A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer | November 30, 2023 | December 31, 2027 |
| NCT06229340 | Recruiting | Phase 2 | Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations | October 3, 2023 | October 1, 2026 |
| NCT04337580 | Recruiting | Phase 2 | Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer | March 5, 2021 | September 2024 |
| NCT04421560 | Recruiting | Phase 1/Phase 2 | Pembrolizumab, Ibrutinib and Rituximab in PCNSL | August 1, 2020 | March 5, 2025 |
| NCT04510636 | Recruiting | Phase 2 | Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma | December 20, 2021 | June 1, 2026 |
| NCT04840004 | Recruiting | Phase 2 | Efficacy and Safety of PVT-1 Treatment in Patients With Advanced Non-Small Cell Lung Cancer | March 10, 2021 | December 31, 2025 |
| NCT05359445 | Recruiting | Phase 1 | IMA401 TCER® in Recurrent and/or Refractory Solid Tumors | May 19, 2022 | November 2027 |
| NCT05504772 | Recruiting | Precision Medicine for Every Child With Cancer | December 16, 2022 | July 2030 | |
| NCT05631574 | Recruiting | Phase 1 | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer | January 12, 2023 | October 2026 |
| NCT05662397 | Recruiting | Phase 1/Phase 2 | A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody | March 15, 2023 | December 31, 2026 |
| NCT05669430 | Recruiting | Phase 1 | A Study of GV20-0251 in Patients With Solid Tumor Malignancies | March 23, 2023 | June 15, 2026 |
| NCT05681195 | Recruiting | Phase 2 | Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas | April 25, 2024 | February 2031 |
| NCT02222363 | Terminated | Phase 1 | Study of Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors | February 18, 2015 | December 28, 2016 |
| NCT01320280 | Terminated | Phase 2 | BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer | May 2011 | November 2012 |
| NCT04092179 | Terminated | Phase 1/Phase 2 | Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers | November 5, 2020 | October 26, 2023 |
| NCT04640246 | Unknown status | Phase 1/Phase 2 | Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies | January 25, 2021 | April 2023 |
| NCT04695223 | Unknown status | Phase 2 | Arsenic Trioxide for Structural p53 Mutations | January 1, 2021 | October 31, 2021 |
| NCT04859777 | Unknown status | Phase 1 | A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors | April 13, 2021 | March 2023 |
| NCT03199677 | Unknown status | Phase 2 | A Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer | July 1, 2017 | June 30, 2018 |
| NCT05302037 | Unknown status | Phase 1 | Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers | April 2022 | December 2023 |
| NCT02747732 | Unknown status | Phase 2 | Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL | December 2016 | October 2021 |
| NCT01932047 | Unknown status | Patients Who Refractory Cancer Conqueror for Bio New Drug Development Translational Research Establishment | April 2010 | April 2015 | |
| NCT05060276 | Withdrawn | Phase 1 | Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors | December 2022 | December 2024 |